Case number 1:25-cv-00276
Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 21, 2025 | 10 | SO ORDERED, re (256 in 1:23-cv-00101-CFC, 7 in 1:25-cv-00276-CFC) Joint MOTION to Consolidate Cases (Case No. 25-276 into Lead Case 23-101-CFC) filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/21/2025. Associated Cases: 1:23-cv-00101-CFC, 1:25-cv-00276-CFC(mws) (Entered: 03/21/2025) (2) |
| Mar 21, 2025 | N/A | Case associated with lead case: Create association to 1:23-cv-00101-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 23-101-CFC ONLY. (mws) (Entered: 03/21/2025) (0) |
| Mar 12, 2025 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 03/12/2025) (0) |
| Mar 12, 2025 | 9 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (mws) (Entered: 03/12/2025) (2) |
| Mar 10, 2025 | N/A | Remark: MDL Panel has been notified. (slk) (Entered: 03/10/2025) (0) |
| Mar 10, 2025 | 7 | JOINT Motion and Proposed Order to Consolidate Case 25-276 into Lead Case 23-101-CFC - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) Modified on 3/11/2025 (nms). (Entered: 03/10/2025) (10) |
| Mar 10, 2025 | 8 | Letter to The Honorable Colm F. Connolly, from Travis J. Murray, regarding context and explanation for request to consolidate. (Murray, Travis) Modified on 3/11/2025 (nms). (Entered: 03/10/2025) (2) |
| Mar 7, 2025 | 1 | COMPLAINT against Mylan Pharmaceuticals Inc. (Filing fee $ 405, receipt number ADEDC-4631856) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(slk). (Entered: 03/10/2025) (0) |
| Mar 7, 2025 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (slk). (Entered: 03/10/2025) (3) |
| Mar 7, 2025 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Date of Expiration of Patent: August 24, 2038.Thirty Month Stay Deadline: 6/17/2025. (slk) (Entered: 03/10/2025) (1) |
| Mar 7, 2025 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,214,017. (slk) (Entered: 03/10/2025) (1) |
| Mar 7, 2025 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S, Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc. (slk) (Entered: 03/10/2025) (2) |
| Mar 7, 2025 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 3/10/2025. (slk). (Entered: 03/10/2025) (2) |
